Curis Receives $3 Million From Genentech

Curis Inc. (CRIS) received a milestone payment of $3 million from partner Genentech Inc. (DNA) for a jointly developed cancer treatment awaiting regulatory approval to enter an early stage clinical trial. Shares of Curis surged 23 cents to $1.58 while Genentech stock gained $1.30 to close at $83.70.